Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovascular Disease in Europe
Europe loses approximately €240 billion every year because of the interconnected burdens of obesity diabetes cardiovascular disease (EFPIA Guest Blog). Fragmented healthcare systems that treat late-stage complications instead of preventing disease progression are largely responsible for this mass...